Pfizer: Vaccine protects adolescents
The COVID-19 vaccine from drug company Pfizer and its German partner Biontech vaccine is safe for and extremely effective in adolescents, according to a company-sponsored study released Wednesday.
In adolescents 12 to 15 years old, vaccination led to a higher protective antibody response than in adults and was seen to be 100% effective against symptomatic disease, the study of 2,260 adolescents found.
The two-shot Pfizer-biontech vaccine had been authorized for use in those 16 and up based on previous trials, but not in younger adolescents.
Last week, the companies began testing their vaccine in children ages 5 to 11; next week, they will begin testing in ages 2 to 5, and later will look at children 6 months to 2 years. The trial results should be available later this year.
Moderna, which also has a COVID-19 vaccine, has been studying its shot in teenagers since December, and launched a trial in younger children in mid-march. That vaccine is not yet approved for use in older teens.
Pfizer and Biontech plan to submit their adolescent data to the U.S. Food and Drug Administration to ask that their authorization to provide BNT162B2 be quickly amended to include that age group. It’s not clear how long the FDA will take to review the request.
Albert Bourla, chairman and CEO of Pfizer, said he hoped to make the vaccine available to younger adolescents.
“We share the urgency to expand the use of our vaccine to additional populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15,” he said in a statement. “We plan to submit these data to FDA as a proposed amendment to our Emergency Use Authorization in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year.”
In the trial, 18 adolescents who received a placebo came down with COVID-19, but none in the vaccinated group, the companies said. Side effects in adolescents were consistent with those observed in participants 16 to 25 years old.
All participants will be monitored for two years after their second dose to track long-term protection and safety.
The BNT162B2 vaccine, like those from Moderna and Johnson & Johnson, has received emergency use authorization rather than full FDA approval. To save time during the pandemic, the companies were allowed to provide two months of safety data, instead of waiting the full two years to see whether the vaccine will remain effective. Serious side effects, if any, are mostly likely to occur within the first six weeks after vaccination.
It remains unclear how long the COVID-19 vaccines will remain protective, but trial results and real-world data suggest the Moderna and Pfizerbiontech vaccines are more than 90% effective at preventing symptomatic COVID-19.
Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.